These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7328994)

  • 1. [Increased desacetylation of rifampicin and an adverse reaction (author's transl)].
    Nakagawa H; Umene Z; Sunahara S
    Kekkaku; 1981 Dec; 56(12):577-86. PubMed ID: 7328994
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rifampicin concentrations in the sputum before and after administration of bromohexine (author's transl)].
    Dold U; Petersen KF
    Prax Klin Pneumol; 1978 Aug; 32(8):543-50. PubMed ID: 683946
    [No Abstract]   [Full Text] [Related]  

  • 3. Rifampicin desacetylation in the human organism.
    Maggi N; Furesz S; Pallanza R; Pelizza G
    Arzneimittelforschung; 1969 Apr; 19(4):651-4. PubMed ID: 5819167
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmaceutical view of rifampicin (author's transl)].
    Tsutsumi S; Sakamoto Y; Gido S
    Repura; 1974; 43(1):1-7. PubMed ID: 4610307
    [No Abstract]   [Full Text] [Related]  

  • 5. [Increase in desacetylated rifampicin and adverse effects (proceedings)].
    Nakagawa H; Umene Z; Sunahara S
    Bull Int Union Tuberc; 1979 Jun; 54(2):182. PubMed ID: 526654
    [No Abstract]   [Full Text] [Related]  

  • 6. Rifampicin.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1980; 24():243-58. PubMed ID: 7009395
    [No Abstract]   [Full Text] [Related]  

  • 7. Fever associated with daily rifampin therapy.
    Nolan RL; Cleary JD; Chapman SW
    Clin Pharm; 1990 Jan; 9(1):57-8. PubMed ID: 2302932
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunosuppressive effects of rifampicin (RFP) (author's transl)].
    Nagai S; Izumi T
    Kekkaku; 1974 Nov; 49(11):375-82. PubMed ID: 4549086
    [No Abstract]   [Full Text] [Related]  

  • 9. [A five year follow-up study of antituberculosis chemotherapy with and without rifampicin (author's transl)].
    Matsumiya T; Yoshida F; Inoue M; Yoshimura M; Ogawa T; Yoshida R; Ishii A
    Kekkaku; 1980 Feb; 55(2):43-51. PubMed ID: 7373965
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin.
    Chan CH; Or KK; Cheung W; Woo J
    J Med; 1995; 26(1-2):43-52. PubMed ID: 7561530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adverse reactions to short-course anti-tuberculous therapy (author's transl)].
    Carrasco E
    Rev Med Chil; 1981 Jun; 109(6):566-72. PubMed ID: 7330536
    [No Abstract]   [Full Text] [Related]  

  • 12. [A report on 10 cases of enlargement of mediastinal lymph nodes occurring during RFP and INH treatment (author's transl)].
    Sun DQ
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1981 Oct; 4(5):262-4. PubMed ID: 7341164
    [No Abstract]   [Full Text] [Related]  

  • 13. [Histological characteristics of tuberculous cavity treated with rifampicin--a comparative study with cases treated by primary drugs (author's transl)].
    Tanaka I; Iwai K
    Kekkaku; 1981 Jul; 56(7):355-60. PubMed ID: 7328996
    [No Abstract]   [Full Text] [Related]  

  • 14. "Flu" syndrome due to rifampin; experience with four cases.
    Dhar S; Kaur I; Sharma VK; Kumar B
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):92-4. PubMed ID: 7730725
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adverse reactions of enviomycin during treatment for pulmonary tuberculosis (author's transl)].
    Miwa T; Tsukamura M; Kawase Y; Mashima T; Horie S; Seki F; Hashizume T; Hayashi S; Kondo I; Ariga F; Tanaka A; Takase K; Kawai M; Tanii Y; Matsutani I; Koketsu Y
    Kekkaku; 1980 Apr; 55(4):201-6. PubMed ID: 7392350
    [No Abstract]   [Full Text] [Related]  

  • 16. [A study on the resistance test for rifampicin (author's transl)].
    Wu AD
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1980 Feb; 3(2):101-3. PubMed ID: 7418547
    [No Abstract]   [Full Text] [Related]  

  • 17. [Corticosteroids in the treatment of cavitating pulmonary tuberculosis (author's transl)].
    Saatçi H; Meral N
    Prax Klin Pneumol; 1980 Jan; 34(1):42-4. PubMed ID: 7367380
    [No Abstract]   [Full Text] [Related]  

  • 18. [The influence of therapeutical and biological parameters on the appearance of side effects and complaints during intermittent chemotherapy of pulmonary tuberculosis (author's transl)].
    Eule H; Iwainsky H
    Prax Klin Pneumol; 1981 Aug; 35(8):347-53. PubMed ID: 7345430
    [No Abstract]   [Full Text] [Related]  

  • 19. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
    Nijland HM; L'homme RF; Rongen GA; van Uden P; van Crevel R; Boeree MJ; Aarnoutse RE; Koopmans PP; Burger DM
    AIDS; 2008 May; 22(8):931-5. PubMed ID: 18453852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reaction to rifampin: a case with long lasting antiplatelet antibodies.
    Tricerri A; Vangeli M; Addario C; Guidi L; Bartoloni C; Magalini S; Gentiloni Silveri N
    Panminerva Med; 1997 Mar; 39(1):64-6. PubMed ID: 9175425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.